Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 9649

New research looks at distinctive differences in brain connectivity that may underlie autism spectrum disorders (ASD) — and possibly provide much-needed biomarkers to aid in identifying the disorder.

Diagnosis for ASD is still behaviorally based. But getting a diagnosis can take longer due to several factors, including lack of resources and trained clinicians. This delays autism diagnosis, on average, until age 5 or 6.

“Within ASD, two important research questions are: How can we minimize the delay in diagnosis, and what kind of intervention can we give the child?” said Rajesh Kana, Ph.D., associate professor of psychology in the UAB College of Arts and Sciences.

Read more

An artist’s rendering of Blue Origin’s New Glenn rocket during its ascent into orbit. Image Credit: Blue Origin.

CAPE CANAVERAL, Fla. — Blue Origin’s New Glenn rocket has been selected by Canadian-based Telesat to send a fleet of satellites into orbit. The payload for these flights could help improve web services around the globe.

The satellites, designed to provide internet services across the globe, will be sent to low-Earth orbit by Texas-based Blue Origin’s New Glenn over the course of multiple launches.

Read more

The new design stores heat generated by excess electricity from solar or wind power in large tanks of white-hot molten silicon, and then converts the light from the glowing metal back into electricity when it’s needed. The researchers estimate that such a system would be much more affordable than lithium-ion batteries, which have been proposed as a viable, though expensive, method to store renewable energy. They also estimate that the system would cost about half as much as pumped hydroelectric storage—the cheapest form of grid-scale energy storage so far.

Delivering solar- or wind-generated power on demand, the system, which uses molten silicon, should be cheaper than other leading options.

Read more

Despite unbelievable advances in medical science in recent decades, breast cancer kills. Approximately 1 in 8 American women will develop breast cancer cells during the course of their lifetime.

Finding a cure is imperative, and as such, fervent research continues. At the European Breast Cancer Conference in Amsterdam, scientists presented a pair of drugs with an astounding claim: this treatment can eradicate some types of breast cancer in only 11 days, eliminating the need for chemotherapy.

Chemotherapy, whilst an amazing feat of medical-scientific engineering, is known for its uncomfortable and sometimes debilitating side effects. Women undergoing chemotherapy for breast cancer treatment may lose their hair, suffer extreme fatigue, and even loss of cognitive function.

Read more